Chapter 104 : Human Parvoviruses

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Human Parvoviruses , Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816728/9781555814632_Chap104-1.gif /docserver/preview/fulltext/10.1128/9781555816728/9781555814632_Chap104-2.gif


The current classification of parvoviruses is based upon their host range and dependence on other viruses for their replication. This chapter focuses primarily on Erythrovirus but does contain brief updates on human bocavirus (HBoV) and the newly described human parvovirus 4 (PARV4). Subsequent evaluation of blood unit, using immune electron microscopy, revealed viral particles consistent in size and morphology with parvovirus. Many important observations regarding the B19 virion have been made using electron microscopy and X-ray crystallography. The major nonstructural protein is NS1 (71 kDa), a DNA binding protein involved in viral replication. The VP1 and VP2 capsid proteins originate from the same ORF and are identical in sequence, except for an additional 227 amino acids at the amino terminus of VP1. Using nucleic acid amplification testing (NAT), B19 DNA has been detected in numerous batches of albumin, factor VIII, factor IX, clotting factor concentrates, and immunoglobulin. Serum from whole blood, collected in a sterile tube lacking anticoagulant, is most suitable for serologic testing, although plasma, containing either EDTA or sodium citrate, can also be used. Capture enzyme immunoassays employing native or recombinant antigens are excellent choices for detecting B19-specific immunoglobulin. Testing sera for the presence of B19-specific IgG antibodies can determine past or previous infection in the immunocompetent individual.

Citation: Jordan J. 2011. Human Parvoviruses , p 1636-1646. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch104
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of FIGURE 1

Schematic representation of human parvovirus B19 genome and the transcription map with the unique region of VP1 comprising bp 2444 to 3124.

Citation: Jordan J. 2011. Human Parvoviruses , p 1636-1646. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch104
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2

Clinical features, hematologic changes, B19 DNA presence, and serologic findings associated with B19 infection in a healthy individual. Reprinted from reference .

Citation: Jordan J. 2011. Human Parvoviruses , p 1636-1646. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch104
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Aberham, C.,, C. Pendl,, P. Gross,, G. Zerlauth,, and M. Gessner. 2001. A quantitative, internally controlled real-time PCR assay for the detection of parvovirus B19 DNA. J. Virol. Methods 92: 183 191.
2. Agbandje, M.,, S. Kajigaya,, R. McKenna,, N. S. Young,, and M. G. Rossmann. 1994. The structure of human parvovirus B19 at 8 A resolution. Virology 203: 106 115.
3. Allander, T. 2008. Human bocavirus. J. Clin. Virol. 41: 29 33.
4. Allander, T.,, M. T. Tammi,, M. Eriksson,, A. Bjerkner,, A. Tiveljung-Lindell,, and B. Andersson. 2005. Cloning of human parvovirus by molecular screening of respiratory tract samples. Proc. Natl. Acad. Sci. USA 102: 12891 12896.
5. Anderson, M. J.,, P. G. Higgins,, L. R. Davis,, J. S. Willman,, S. E. Jones,, I. M. Kidd,, J. R. Pattison,, and D. A. Tyrrell. 1985. Experimental parvoviral infection in humans. J. Infect.Dis. 152: 257 265.
6. Anderson, M. J.,, S. E. Jones,, S. P. Fisher-Hoch,, E. Lewis,, S. M. Hall,, C. L. Bartlett,, B. J. Cohen,, P. P. Mortimer,, and M. S. Pereira. 1983. Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet i: 1378.
7. Arthur, J. L.,, G. D. Higgins,, G. P. Davidson,, R. C. Givney,, and R. M. Ratcliff. 2009. A novel bocavirus associated with acute gastroenteritis in Australian children. PLoS Pathog. 5(4): 1 11.
8. Bagot, M.,, and J. Revuz. 1991. Papular-purpuric ‘gloves and socks’ syndrome: primary infection with parvovirus B19? J. Am. Acad. Dermatol. 25: 341. (Letter.)
9. Bastien, N.,, N. Chui,, J. L. Robinson,, B. E. Lee,, K. Dust,, L. Hart,, and Y. Li. 2007. Detection of human bocavirus in Canadian children in a 1-year study. J. Clin. Microbiol. 45: 610 613.
10. Berns, K. I., 1996. Parvoviridae: theviruses and their replication, p. 2173 2197. In B. N. Fields,, D. M. Knipe,, and P. M. Howley (ed.), Fields Virology, 3rd ed. Lippincott-Raven, Philadelphia, PA.
11. Bonvicini, F.,, G. Gallinella,, M. Cricca,, S. Ambretti,, S. Delbarba,, M. Musiani,, and M. Zerbini. 2004. Molecular testing for detection of in vitro infectivity of plasma pools contaminated with B19 virus. J. Med. Virol. 74: 272 276.
12. Braham, S.,, J. Gandhi,, S. Beard,, and B. Cohen. 2004. Evaluation of the Roche LightCycler parvovirus B19 quantification kit for the diagnosis of parvovirus B19 infections. J. Clin. Virol. 31: 5 10.
13. Brown, K. E.,, S. M. Anderson,, and N. S. Young. 1993. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 262: 114 117.
14. Brown, K. E.,, S. W. Green,, J. Antunez de Mayolo,, J. A. Bellanti,, S. D. Smith,, T. J. Smith,, and N. S. Yound. 1994. Congenital anaemia after transplacental B19 parvovirus infection. Lancet 343: 895 896.
15. Brown, K. E.,, J. R. Hibbs,, G. Gallinella,, S. M. Anderson,, E. D. Lehman,, P. McCarthy,, and N. S. Young. 1994. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N. Engl. J. Med. 330: 1192 1196.
16. Brown, K. E.,, and N. S. Young. 1995. Parvovirus B19 infection and hematopoiesis. Blood Rev. 9: 176 182.
17. Brown, K. E.,, N. S. Young,, B. M. Alving,, and L. H. Barbosa. 2001. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 41: 130 135.
18. Brown, T.,, A. Anand,, L. D. Ritchie,, J. P. Clewley,, and T. M. Reid. 1984. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet ii: 1033 1034.
19. Butchko, A. R.,, and J. A. Jordan. 2004. Comparison of three commercially available serologic assays used to detect human parvovirus B19-specific immunoglobulin M (IgM) and IgG antibodies in sera of pregnant women. J. Clin. Microbiol. 42: 3191 3195.
20. Caliskan, R.,, S. Masatlioglu,, M. Aslan,, S. Altun,, S. Saribas,, S. Erigin,, E. Uckan,, V. Koksal,, V. Oz,, K. Altas,, I. Fresko,, and B. Kocazeybeck. 2005. The relationship between arthritis and human parvovirus B19 infection. Rheumatol. Int. 26: 7 11. [Epub ahead of print.]
21. Canaan, S.,, Z. Zadori,, F. Ghomashchi,, J. Bollinger,, M. Sadilek,, M. E. Moreau,, P. Tijssen,, and M. H. Gelb. 2004. Interfacial enzymology of parvovirus phospholipases A2. J. Biol. Chem. 279: 14502 14508.
22. Candotti, D.,, N. Etiz,, A. Parsyan,, and J. P. Allain. 2004. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J. Virol. 78: 12169 12178.
23.Centers for Disease Control. 1989. Risks associated with human parvovirus B19 infection. MMWR Morb. Mortal. Wkly. Rep. 38: 8197.
24. Chapman, S. A.,, K. L. Gelkerson,, T. D. Davin,, and M. R. Pritzker. 2004. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann. Pharmacother. 38: 2059 2067.
25. Chipman, P. R.,, M. Agbandje-McKenna,, S. Kajigaya,, K. E. Brown,, N. S. Young,, T. S. Baker,, and M. G. Rossmann. 1996. Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor. Proc. Natl. Acad. Sci. USA 93: 7502 7506.
26. Chow, B. D.,, Y. T. Huang,, and F. P. Esper. 2008. Evidence of human bocavirus circulating in children and adults, Cleveland, Ohio. J. Clin. Virol. 43: 302 306.
27. Chow, B. D. W.,, Z. Ou,, and F. P. Esper. 2010. Newly recognized bocaviruses (HBoV, HBoV2) in children and adults with gastrointestinal illness in the United States. J. Clin. Virol. 47: 143 147. [Epub ahead of print.]
28. Clewley, J. P. 1984. Biochemical characterization of a human parvovirus. J. Gen. Virol. 65: 241 245.
29. Cohen, B. J.,, and C. M. Bates. 1995. Evaluation of 4 commercial test kits for parvovirus B19-specific IgM. J. Virol. Methods 55: 11 25.
30. Cohen, B. J.,, J. Gandhi,, and J. P. Clewley. 2006. Genetic variants of parvovirus B19 identified in the United Kingdom: implications for diagnostic testing. J. Clin. Virol. 36: 152 155.
31. Cooling, L. L.,, T. A. Koerner,, and S. J. Naides. 1995. Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. J. Infect. Dis. 172: 1198 1205.
32. Cossart, Y. E.,, A. M. Field,, B. Cant,, and D. Widdows. 1975. Parvovirus-like particles in human sera. Lancet i: 72 73.
33. Curry, A.,, H. Appleton,, and B. Dowsett. 2006. Application of transmission electron microscopy to the clinical study of viral and bacterial infections: present and future. Micron 37: 91 106.
34. Delle Chiaie, L.,, G. Buck,, D. Grab,, and R. Terinde. 2001. Prediction of fetal anemia with Doppler measurement of the middle cerebral artery peak systolic velocity in pregnancies complicated by maternal blood group alloimmunization or parvovirus B19 infection. Ultrasound Obstet. Gynecol. 18: 232 236.
35. Devine, P. A. 2002. Parvovirus infection in women. Prim. Care Update Ob/Gyns 9: 149 153.
36. Erdman, D. D.,, B. C. Anderson,, T. J. Torok,, T. H. Finkel,, and L. J. Anderson. 1997. Possible transmission of parvovirus B19 from intravenous immune globulin. J. Med. Virol. 53: 233 236.
37. Ferguson, M.,, and A. Heath. 2004. Report of a collaborative study to calibrate the Second International Standard for parvovirus B19 antibody. Biologicals 32(2): 207 212.
38. French, A. L.,, L. Sacks,, and G. P. Schechter. 1996. Fifth disease after immunoglobulin administration in an AIDS patient with parvovirus-induced red cell aplasia. Am. J. Med. 101: 108 109.
39. Fryer, J. F.,, E. Delwart,, F. M. Hecht,, F. Bernardin,, M. S. Jones,, N. Shah,, and S. A. Baylis. 2007. Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion 47: 1054 1061.
40. Fryer, J. F.,, A. R. Hubbard,, and S. A. Baylis. 2007. Human parvovirus PARV4 in clotting factor VIII concentrates. Vox Sang. 93: 341 347.
41. Gallinella, G.,, E. Manaresi,, S. Venturoli,, G. L. Grazi,, M. Musiani,, and M. Zerbini. 1999. Occurrence and clinical role of active parvovirus B19 infection in transplant recipients. Eur. J. Clin. Microbiol. Infect. Dis. 18: 811 813.
42. Harder, T. C.,, M. Hufnagel,, K. Zahn,, K. Beutel,, H. J. Schmitt,, U. Ullmann,, and P. Rautenberg. 2001. New Light- Cycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infections. J. Clin. Microbiol. 39: 4413 4419.
43. Hayakawa, F.,, K. Imada,, M. Towatari,, and H. Saito. 2002. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br. J. Haematol. 118: 1187 1189.
44. Heegaard, E. D.,, and K. E. Brown. 2002. Human parvovirus B19. Clin. Microbiol. Rev. 15: 485 505.
45. Heegaard, E. D.,, I. Panum Jensen,, and J. Christensen. 2001. Novel PCR assay for differential detection and screening of erythrovirus B19 and erythrovirus V9. J. Med. Virol. 65: 362 367.
46. Heegaard, E. D.,, C. J. Rasksen,, and J. Christensen. 2000. Detection of parvovirus B19 NS1-specific antibodies by ELISA and Western blotting employing recombinant NS1 protein as antigen. FEMS Immunol. Med. Microbiol. 27: 9 15.
47. Hokynar, K.,, P. Norja,, H. Laitinen,, P. Palomaki,, A. Garbarg-Chenon,, A. Ranki,, K. Hedman,, and M. Soderlund-Venermo. 2004. Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests. J. Clin. Microbiol. 42: 2013 2019.
48. Jones, L. P.,, D. D. Erdman,, and L. J. Anderson. 1999. Prevalence of antibodies to human parvovirus B19 nonstructural protein in persons with various clinical outcomes following B19 infection. J. Infect. Dis. 180: 500 504.
49. Jones, M. S.,, A. Kapoor,, V. V. Lukashow,, P. Simmonds,, F. Hecht,, and E. Delwart. 2005. New DNA viruses identified in patients with acute viral infection syndrome. J. Virol. 79: 8230 8236.
50. Jordan, J.,, B. Tiangco,, J. Kiss,, and W. Koch. 1998. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang. 75: 97 102.
51. Jordan, J. A. 2000. Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia coli-based VP1 EIA for detection of human parvovirus B19 immunoglobulin M and immunoglobulin G in sera of pregnant women. J. Clin. Microbiol. 38: 1472 1475.
52. Jordan, J. A. 2001. Diagnosing human parvovirus B19 infection: guidelines for test selection. Mol. Diagn. 6: 307 312.
53. Jordan, J. A. 1996. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am. J. Obstet. Gynecol. 174: 37 42.
54. Jordan, J. A.,, and A. R. Butchko. 2002. Apoptotic activity in villous trophoblast cells during B19 infection correlates with clinical outcome: assessment by the caspase-related M30 Cytodeath antibody. Placenta 23: 547 553.
55. Jordan, J. A.,, and J. A. DeLoia. 1999. Globoside expression within the human placenta. Placenta 20: 103 108.
56. Jordan, J. A.,, S. J. Faas,, E. R. Braun,, and M. Trucco. 1996. Exonuclease-released fluorescence detection of human parvovirus B19 DNA. Mol. Diagn. 1: 321 328.
57. Jordan, J. A.,, D. Huff,, and J. A. DeLoia. 2001. Placental cellular immune response in women infected with human parvovirus B19 during pregnancy. Clin. Diagn. Lab. Immunol. 8: 288 292.
58. Jordan, J. A.,, and L. Penchansky. 1995. Diagnosis of human parvovirus B19-induced anemia: correlation of bone marrow morphology with molecular diagnosis using PCR and immunocytochemistry. Cell Vision 2: 279 282.
59. Kahn, J. 2008. Human bocavirus: clinical significance and implications. Curr. Opin. Pediatr. 20: 62 66.
60. Kajigaya, S.,, H. Fujii,, A. Field,, S. Anderson,, S. Rosenfeld,, L. J. Anderson,, T. Shimada,, and N. S. Young. 1991. Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc. Natl. Acad. Sci. USA 88: 4646 4650.
61. Kantola, K.,, L. Hedman,, T. Allander,, T. Jartti,, P. Lehtinen,, O. Ruuskanen,, K. Hedman,, and M. Söderlund-Venermo. 2008. Serodiagnosis of human bocavirus infection. Clin. Infect. Dis. 46: 540 546.
62. Kaufmann, B.,, A. A. Simpson,, and M. G. Rossmann. 2004. The structure of human parvovirus B19. Proc. Natl. Acad. Sci. USA 101: 11628 11633.
63. Kerr, J. R. 2000. Pathogenesis of human parvovirus B19 in rheumatic disease. Ann. Rheum. Dis. 59: 672 683.
64. Kerr, J. R.,, V. S. Cunniffe,, P. Kelleher,, R. M. Bernstein,, and I. N. Bruce. 2003. Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome. Clin. Infect. Dis. 36: 100 106.
65. Kerr, S.,, G. O’Keeffe,, C. Kilty,, and S. Doyle. 1999. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. J. Med. Virol. 57: 179 185.
66. Kleinman, S. H.,, S. A. Glynn,, T. H. Lee,, L. H. Tobler,, K. S. Schlumpf,, D. S. Todd,, H. Qiao,, M. Y. Yu,, and M. P. Busch. 2009. A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 114(17): 3677 3683.
67. Kuo, S. H.,, L. I. Lin,, C. J. Chang,, Y. R. Liu,, K. S. Lin,, and A. L. Cheng. 2002. Increased risk of parvovirus B19 infection in young adult cancer patients receiving multiple courses of chemotherapy. J. Clin. Microbiol. 40: 3909 3912.
68. Lau, S. K. P.,, C. C. Y. Yip,, T. I. Que,, R. A. Less,, R. K. H. Au-Yeung,, B. Zhou,, L. So,, Y. Lau,, K. Chan,, P. C. Y. Woo,, and K. Yuen. 2007. Clinical and molecular epidemiology of human bocavirus in respiratory and fecal samples from children in Hong Kong. J. Infect. Dis. 196: 986 993.
69. Lefrere, J. J.,, M. Mariotti,, and M. Thauvin. 1994. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lancet 343: 211 212.
70. Liefeldt, L.,, A. Plentz,, B. Klempa,, O. Kershaw,, A. S. Endres,, U. Raab,, H. H. Neumayer,, H. Meisel,, and S. Modrow. 2005. Recurrent high level parvovirus B19/genotype 2 viremia in a renal transplant recipient analyzed by real-time PCR for simultaneous detection of genotypes 1 to 3. J. Med. Virol. 75: 161 169.
71. Lurcharchaiwong, W.,, T. Chieochansin,, S. Payungporn,, A. Theamboonlers,, and Y. Poovorawan. 2008. Parvovirus 4 (PARV4) in serum of intravenous drug users and blood donors. Infection 36: 488 491.
72. Manaresi, E.,, G. Gallinella,, S. Venturoli,, M. Zerbini,, and M. Musiani. 2004. Detection of parvovirus B19 IgG: choice of antigens and serological tests. J. Clin. Virol. 29: 51 53.
73. Manaresi, E.,, G. Gallinella,, M. Zerbini,, S. Venturoli,, G. Gentilomi,, and M. Musiani. 1999. IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay. J. Med. Virol. 57: 174 178.
74. Manaresi, E.,, P. Pasini,, G. Gallinella,, G. Gentilomi,, S. Venturoli,, A. Roda,, M. Zerbini,, and M. Musiani. 1999. Chemiluminescence Western blot assay for the detection of immunity against parvovirus B19 VP1 and VP2 linear epitopes using a videocamera based luminograph. J. Virol. Methods 81: 91 99.
75. Manaresi, E.,, E. Zuffi,, G. Gallinella,, G. Gentilomi,, M. Zerbini,, and M. Musiani. 2001. Differential IgM response to conformational and linear epitopes of parvovirus B19 VP1 and VP2 structural proteins. J. Med. Virol. 64: 67 73.
76. Manning, A.,, V. Russell,, K. Eastick,, G. H. Leadbetter,, N. Hallam,, K. Templeton,, P. Simmonds. 2006. Epidemiological profile and clinical associations of human bocavirus and other human parvoviruses. J. Infect. Dis. 194: 1283 1290.
77. Manning, A.,, S. J. Willey,, J. E. Bell,, and P. Simmonds. 2007. Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus. J. Infect Dis. 195: 1345 1352.
78. McGhee, S. A.,, B. Kaska,, M. Liebhaber,, and E. R. Stiehm. 2005. Persistent parvovirus associated chronic fatigue treated with high dose intravenous immunoglobulin. Pediatr. Infect. Dis. J. 24: 272 274.
79. McOmish, F.,, P. L. Yap,, A. Jordan,, H. Hart,, B. J. Cohen,, and P. Simmonds. 1993. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J. Clin. Microbiol. 31: 323 328.
80. Moffatt, S.,, N. Tanaka,, K. Tada,, M. Nose,, M. Nakamura,, O. Muraoka,, T. Hirano,, and K. Sugamura. 1996. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J. Virol. 70: 8485 8491.
81. Moffatt, S.,, N. Yaegashi,, K. Tada,, N. Tanaka,, and K. Sugamura. 1998. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J. Virol. 72: 3018 3028.
82. Morinet, F.,, L. D’Auriol,, J. D. Tratschin,, and F. Galibert. 1989. Expression of the human parvovirus B19 protein fused to protein A in Escherichia coli: recognition by IgM and IgG antibodies in human sera. J. Gen. Virol. 70: 3091 3097.
83. Morita, E.,, A. Nakashima,, H. Asao,, H. Sato,, and K. Sugamura. 2003. Human parvovirus B19 nonstructural protein (NS1) induces cell cycle arrest at G1 phase. J. Virol. 77: 2915 2921.
84. Mostello, D.,, W. L. Holcomb, Jr.,, J. M. Talsky,, and H. N. Winn. 2004. Fetal parvovirus B19 infection: Doppler studies allow noninvasive treatment of ascites. J. Ultrasound Med. 23: 557 560.
85. Mouthon, L.,, L. Guillevin,, and Z. Tellier. 2005. Intravenous immunoglobulins in autoimmune- or parvovirus B19- mediated pure red-cell aplasia. Autoimmun. Rev. 4: 264 269.
86. Munakata, Y.,, T. Saito-Ito,, K. Kumura-Ishii,, J. Huang,, T. Kodra,, T. Ishii,, Y. Hirabayashi,, Y. Koyanagi,, and T. Sasaki. 2005. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 106: 3449 3456.
87. Musiani, M.,, A. Azzi,, M. Zerbini,, D. Gibellini,, S. Venturoli,, K. Zakrzewska,, M. C. Re,, G. Gentilomi,, G. Gallinella,, and M. La Placa. 1993. Nested polymerase chain reaction assay for the detection of B19 parvovirus DNA in human immunodeficiency virus patients. J. Med. Virol. 40: 157 160.
88. Musiani, M.,, E. Manaresi,, G. Gallinella,, S. Venturoli,, E. Zuffi,, and M. Zerbini. 2000. Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1. J. Med. Virol. 60: 347 352.
89. Musiani, M.,, M. Zerbini,, G. Gentilomi,, M. Plazzi,, G. Gallinella,, and S. Venturoli. 1995. Parvovirus B19 clearance from peripheral blood after acute infection. J. Infect. Dis. 172: 1360 1363.
90. Musiani, M.,, M. Zerbini,, G. Gentilomi,, G. Rodorigo,, V. De Rosa,, D. Gibellini,, S. Venturoli,, and G. Gallinella. 1995. Persistent B19 parvovirus infections in haemophilic HIV-1 infected patients. J. Med. Virol. 46: 103 108.
91. Naides, S. J.,, L. L. Scharosch,, F. Foto,, and E. J. Howard. 1990. Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience. Arthritis Rheum. 33: 1297 1309.
92. National Institute for Biological Standards and Control (NIBSC). 2004. WHO International Standard for Parvovirus B19 DNA for Nucleic Acid Amplification (NAT) Assays. NIBSC Code 99/800. Instructions for Use (17 February 2004, version.5). National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom.
93. Nguyen, Q. T.,, S. Wong,, E. D. Heegaard,, and K. E. Brown. 2002. Identification and characterization of a second novel human erythrovirus variant, A6. Virology 301: 374 380.
94. Norja, P.,, A. M. Eis-Hübinger,, M. Söderlund-Verermo,, K. Hedman,, and P. Simmonds. 2008. Rapid sequence change and geographical spread of human parvovirus B19: comparison of B19 virus evolution in acute and persistent infections. J. Virol. 82: 6427 6433.
95. Ozawa, K.,, and N. Young. 1987. Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. J. Virol. 61: 2627 2630.
96. Parsyan, A.,, C. Szmaragd,, J. P. Allain,, and D. Candotti. 2007. Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes. J. Gen. Virol. 88: 428 431.
97. Pattison, J. R.,, S. E. Jones,, J. Hodgson,, L. R. Davis,, J. M. White,, C. E. Stroud,, and L. Murtaza. 1981. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet i: 664 665.
98. Pereira, R. F.,, W. N. Paula,, C. Cubel Rde,, and J. P. Nascimento. 2001. Anti-VP1 and anti-VP2 antibodies detected by immunofluorescence assays in patients with acute human parvovirus B19 infection. Mem. Instit. Oswaldo Cruz 96: 507 513.
99. Pfrepper, K. I.,, M. Enders,, and M. Motz. 2005. Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection. J. Vet. Med. B 52: 362 365.
100. Potter, C. G.,, A. C. Potter,, C. S. Hatton,, H. M. Chapel,, M. J. Anderson,, J. R. Pattison,, D. A. Tyrrell,, P. G. Higgins,, J. S. Willman,, H. F. Parry, et al. 1987. Variation of erythroid and myeloid precursors in the marrow and peripheral blood of volunteer subjects infected with human parvovirus (B19). J. Clin. Investig. 79: 1486 1492.
101.Public Health Laboratory Service Working Partyon Fifth Disease. 1990. Prospective study of human parvovirus (B19) infection in pregnancy. Br. Med. J. 300: 11661170.
102. Raab, U.,, K. Beckenlehner,, T. Lowin,, H. H. Niller,, S. Doyle,, and S. Modrow. 2002. NS1 protein of parvovirus B19 interacts directly with DNA sequences of the p6 promoter and with the cellular transcription factors Sp1/Sp3. Virology 293: 86 93.
103. Reid, D. M.,, T. M. Reid,, T. Brown,, J. A. Rennie,, and C. J. Eastmond. 1985. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet i: 422 425.
104. Riipinen, A.,, E. Väisänen,, A. Lahtinen,, R. Karikoski,, M. Nuutila,, H. M. Surcel,, H. Taskinen,, K. Hedman,, and M. Söderlund-Venermo. 2010. Absence of human bocavirus from deceased fetuses and their mothers. J. Clin. Virol. 47: 186 188. [Epub ahead of print.]
105. Robertson, B. H.,, and D. D. Erdman. 2000. Non-enveloped viruses transmitted by blood and blood products. Dev. Biol. Stand. 102: 29 35.
106. Saikawa, T.,, S. Anderson,, M. Momoeda,, S. Kajigaya,, and N. S. Young. 1993. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J. Virol. 67: 3004 3009.
107. Saldanha, J.,, and P. Minor. 1996. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br. J. Haematol. 93: 714 719.
108. Sanabani, S.,, W. K. Neto,, J. Pereira,, and E. C. Sabino. 2006. Sequence variability of human erythroviruses present in bone marrow of Brazilian patients with various parvovirus B19-related hematological symptoms. J. Clin. Microbiol. 44: 604 606.
109. Schenk, T.,, M. Enders,, S. Pollak,, R. Hahn,, and D. Huzly. 2009. High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy. J. Clin. Microbiol. 47: 106 110.
110. Schildgen, O.,, A. Müller,, T. Allander,, I. M. Mackay,, S. Völz,, B. Kupfer,, and A. Simon. 2008. Human bocavirus: passenger or pathogen in acute respiratory tract infections? Clin. Microbiol. Rev. 21: 291 304.
111. Servant, A.,, S. Laperche,, F. Lallemand,, V. Marinho,, G. De Saint Maur,, J. F. Meritet,, and A. Garbarg-Chenon. 2002. Genetic diversity within human erythroviruses: identification of three genotypes. J. Virol. 76: 9124 9134.
112. Shade, R. O.,, M. C. Blundell,, S. F. Cotmore,, P. Tattersall,, and C. R. Astell. 1986. Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J. Virol. 58: 921 936.
113. Shirkoohi, R.,, R. Endo,, N. Ishiguro,, S. Teramoto,, H. Kikuta,, and T. Ariga. 2010. Antibodies against structural and nonstructural proteins of human bocavirus in human sera. Clin. Vaccine Immunol. 17: 190 193.
114. Simmonds, P.,, J. Douglas,, G. Bestetti,, E. Longhi,, S. Antinori,, C. Parravicini,, and M. Corbellino. 2008. A third genotype of the human parvovirus PARV4 in sub-Saharan Africa. J. Gen. Virol. 89: 2299 2302.
115. Sklavounou-Andrikopoulou, A.,, M. Iakovou,, S. Paikos,, V. Papanikolaou,, D. Loukeris,, and M. Voulgarelis. 2004. Oral manifestations of papular-purpuric ‘gloves and socks’ syndrome due to parvovirus B19 infection: the first case presented in Greece and review of the literature. Oral Dis. 10: 118 122.
116. Sloots, T. P.,, P. McErlean,, D. J. Speicher,, K. E. Arden,, M. D. Nissen,, and I. M. Mackay. 2006. Evidence of human coronavirus HKU1 and human bocavirus in Australian children. J. Clin. Virol. 35: 99 102.
117. Soderlund, M.,, C. S. Brown,, B. J. Cohen,, and K. Hedman. 1995. Accurate serodiagnosis of B19 parvovirus infections by measurement of IgG avidity. J. Infect. Dis. 171: 710 713.
118. Tabor, E.,, and J. S. Epstein. 2002. NAT screening of blood and plasma donations: evolution of technology and regulatory policy. Transfusion 42: 1230 1237.
119. Takahashi, T.,, K. Ozawa,, K. Takahashi,, S. Asano,, and F. Takaku. 1990. Susceptibility of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation. Blood 75: 603 610.
120. Tattersall, P.,, and S. F. Cotmore,. 1990. Reproduction of autonomous parvovirus DNA, p. 123 140. In P. Tijssen (ed.), Handbook of Parvoviruses, vol. 1. CRC Press, Boca Raton, FL.
121. Tolfvenstam, T.,, N. Papadogiannakis,, O. Norbeck,, K. Petersson,, and K. Broliden. 2001. Frequency of human parvovirus B19 infection in intrauterine fetal death. Lancet 357: 1494 1497.
122. Torok, T. H. 1997. Unusual clinical manifestations reported in patients with parvovirus B19 infection. Monogr. Virol. 20: 61 92.
123. Valeur-Jensen, A. K.,, C. B. Pedersen,, T. Westergaard,, I. P. Jensen,, M. Lebech,, P. K. Andersen,, P. Aaby,, B. N. Pedersen,, and M. Melbye. 1999. Risk factors for parvovirus B19 infection in pregnancy. JAMA 281: 1099 1105.
124. van Regenmortel, M. H. V.,, C. M. Fauquet,, D. H. L. Bishop,, E. B. Carstens,, M. K. Estes,, S. M. Lemon,, J. Maniloff,, M. A. Mayo,, D. J. McGeoch,, C. R. Pringle,, and R. B. Wickner (ed.). 2000. Virus Taxonomy: Classification and Nomenclature of Viruses. Seventh Report of the International Committee on Taxonomy of Viruses. Academic Press, San Diego, CA.
125. Viguier, M.,, L. Guillevin,, and L. Laroche. 2001. Treatment of parvovirus B19-associated polyarteritis nodosa with intravenous immune globulin. N. Eng. J. Med. 344: 1481 1482.
126. Vo, A. A.,, V. Cam,, M. Toyoda,, D. P. Puliyanda,, M. Lukovsky,, and S. C. Jordan. 2006. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin. J. Am. Soc. Nephrol. 1: 844 852.
127. von Poblotzki, A.,, A. Gigler,, B. Lang,, H. Wolf,, and S. Modrow. 1995. Antibodies to parvovirus B19 NS-1 protein in infected individuals. J. Gen. Virol. 76: 519 527.
128. Wang, K.,, W. Wang,, H. Yan,, P. Ren,, J. Zhang,, J. Shen,, and V. Deubel. 2010. Correlation between bocavirus infection and humoral response, and co-infection with other respiratory viruses in children with acute respiratory infection. J. Clin. Virol. 47: 148 155.
129. Wegner, C. C.,, and J. A. Jordan. 2004. Human parvovirus B19 VP2 empty capsids bind to human villous trophoblast cells in vitro via the globoside receptor. Infect. Obstet. Gynecol. 12: 69 78.
130. Weigel-Kelley, K. A.,, M. C. Yoder,, and A. Srivastava. 2003. a5b1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of b1 integrin for viral entry. Blood 102: 3927 3933.
131. Weigel-Kelley, K. A.,, M. C. Yoder,, and A. Srivastava. 2001. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J. Virol. 75: 4110 4116.
132. Weimer, T.,, S. Streichert,, C. Watson,, and A. Groner. 2001. High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion 41: 1500 1504.
133. White, D. G.,, A. D. Woolf,, P. P. Mortimer,, B. J. Cohen,, D. R. Blake,, and P. A. Bacon. 1985. Human parvovirus arthropathy. Lancet i: 419 421.
134. Yaegashi, N.,, T. Niinuma,, H. Chisaka,, T. Watanabe,, S. Uehara,, K. Okamura,, S. Moffatt,, K. Sugamura,, and A. Yajima. 1998. The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. J. Infect. 37: 28 35.
135. Young, N. S. 1996. Parvovirus infection and its treatment. Clin. Exp. Immunol. 104(Suppl. 1): 26 30.
136. Zadori, Z.,, J. Szelei,, M. C. Lacoste,, Y. Li,, S. Gariepy,, P. Raymond,, M. Allaire,, I. R. Nabi,, and P. Tijssen. 2001. A viral phospholipase A2 is required for parvovirus infectivity. Dev. Cell 1: 291 302.
137. Zerbini, M.,, G. Gallinella,, E. Manaresi,, M. Musiani,, G. Gentilomi,, and S. Venturoli. 1999. Standardization of a PCR-ELISA in serum samples: diagnosis of active parvovirus B19 infection. J. Med. Virol. 59: 239 244.
138. Zhi, N.,, Z. Zadori,, K. E. Brown,, and P. Tijssen. 2004. Construction and sequencing of an infectious clone of the human parvovirus B19. Virology 318: 142 152.


Generic image for table

Diagnostic methods used to detect human parvovirus B19 infections

Citation: Jordan J. 2011. Human Parvoviruses , p 1636-1646. In Versalovic J, Carroll K, Funke G, Jorgensen J, Landry M, Warnock D (ed), Manual of Clinical Microbiology, 10th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816728.ch104

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error